Development of novel N-methyl and N-allyl-substituted oxazolomorphinans and their interaction with opioid receptors
© Sipos et al; licensee BioMed Central Ltd. 2011
Published: 5 September 2011
The need for opioid analgesics with reduced undesirable side-effects has initiated a vast amount of scientific efforts, which have led to a number of new opioid ligands and significant expansion of knowledge in opioid pharmacology. The development of morphinans anellated with heterocycles gave rise to several potential therapeutic agents and useful pharmacological tools.
The chemistry involved the design and synthesis of two sets of oxazolomorphinans having the new heteroring anellated to the A-ring of the morphinan backbone. Binding affinities of the newly synthesized compounds at opioid receptors were determined by in vitro competition binding assays using rat brain (μ, δ) and guinea pig brain (κ) membranes and employing [3H]DAMGO (μ), [3H][Ile5,6]deltorphin II (δ) and [3H]U-69,593 (κ) as specific opioid radioligands. The in vitro pharmacological activities were established using [35S]GTPγS functional assays in membranes from Chinese hamster ovary (CHO) cells expressing human opioid receptors.
Binding studies on the newly synthesized N-methyl and N-allyl derivatives to opioid receptors revealed remarkable results for three compounds: the amino-substituted N-methyloxazolomorphinan showed high affinity and selectivity to the μ opioid receptor, while two N-allyloxazolomorphinans were found to interact with high affinity with μ and κ sites and moderate binding towards δ receptors. In ligand-stimulated [35S]GTPγS binding studies, the N-methyl congener acted as a potent and full agonist at the μ receptor. The two N-allyl derivatives showed antagonistic effects at μ and κ receptors.
The design and synthesis of novel oxazolomorphinans led to an interesting alteration in opioid activity by influencing the biological and pharmacological profile of these compounds interacting with μ, δ and κ opioid receptors.
Supported by the Hungarian Research Fund (K81701) and the Austrian Science Fund (FWF: P15481 and TRP 19-B18).
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.